Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-420 in beta-thalassemia and rare anemias
NCT03801889Phase 2Withdrawn
- Sponsor
- AbFero Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of petadeferitrin in iron overload, beta thalassemia, aplastic anemia and 1 more (3 cohorts), sponsored by AbFero Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent Adverse Events at 52 weeks. Planned start Aug 2020; status: withdrawn.
02
Drugs
petadeferitrin
03
Conditions
iron overloadbeta thalassemiaaplastic anemiapure red cell aplasia (PRCA)
Beyond the preview
Go deeper on NCT03801889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801889.